Expression of serum amyloid A protein in the absence of the acute phase response does not reduce HDL cholesterol or apoA-I levels in human apoA-I transgenic mice

Journal of Lipid Research

Volumn 40, Issue 4, 1999, Pages 648-653

  Hosoai, Hiroshi ^a   Webb, Nancy R ^b   Glick, Jane M ^a   Tietge, Uwe J F ^a   Purdom, Matthew S ^b   De Beer, Frederick C ^b   Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Acute phase response; Adenoviral gene transfer; Apolipoprotein A I; HDL metabolism; Serum amyloid A

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SERUM AMYLOID A;

ACUTE PHASE RESPONSE; ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GENE TRANSFER; INFLAMMATION; LIPOPROTEIN METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; VIRUS RECOMBINANT;

ACUTE-PHASE REACTION; ADENOVIRIDAE; ANIMALS; APOLIPOPROTEIN A-I; CHOLESTEROL, HDL; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; HUMANS; KINETICS; LIPOPOLYSACCHARIDES; MICE; MICE, TRANSGENIC; RECOMBINANT PROTEINS; SERUM AMYLOID A PROTEIN;

EID: 0032933232     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Gordon, D. J., and B. M. Rifkind. 1989. High-density lipoproteins - the clinical implications of recent studies. N. Engl. J. Med. 321: 1311-1316.
2. Brinton, E. A., S. Eisenberg, and J. L. Breslow. 1989. Elevated high density lipoprotein cholesterol levels correlate with decreased apolipoprotein A-I and A-II fractional catabolic rate in women. J. Clin. Invest. 84: 262-269.
3. Brinton, E. A., S. Eisenberg, and J. L. Breslow. 1991. Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. J. Clin. Invest. 87: 536-544.
4. Breslow, J. L., S. Eisenberg, and E. A. Brinton. 1993. Metabolic determinants of low HDL-C levels. Ann. NY Acad. Sci. 676: 157-162.
5. Rader, D. J., and K. Ikewaki. 1996. Unravelling high density lipoprotein-apolipoprotein metabolism in human mutants and animal models. Curr. Opin. Lipidol. 7: 117-123.
6. Bausserman, L., D. Vernier, K. McAdam, and P. Herbert. 1988. Serum amyloid A and high density lipoproteins during the acute phase response. Eur. J. Clin. Invest. 18: 619-626.
7. Rossner, S. 1978. Further studies on serum lipoproteins in connective tissue diseases. Atherosclerosis. 31: 93-99.
8. Hardardottir, I., C. Grunfeld, and K. R. Feingold. 1994. Effects of endotoxin and cytokines on lipid metabolism. Curr. Opin. Lipidol. 5: 207-215.
9. Malle, E., A. Steinmetz, and J. G. Raynes. 1993. Serum amyloid A (SAA): an acute phase protein and apolipoprotein. Atherosclerosis. 102: 131-146.
10. Lakatos, J., and A. Harsagyi. 1988. Serum total, HDL, LDL cholesterol, and triglyceride levels in patients with rheumatoid arthritis. Clin. Biochem. 21: 93-96.
11. Seishima, M., S. Mori, and A. Noma. 1994. Serum lipid and apolipoprotein levels in patients with psoriasis. Br. J. Dermatol. 130: 738-742.
12. Coetzee, G., A. Strachan, D. Van der Westhuyzen, H. Hoppe, M. Jeenah, and F. De Beer. 1986. Serum amyloid A-containing human high density lipoprotein 3: density, size, and apolipoprotein composition. J. Biol. Chem. 261:9644-9651.
13. Parks, J., and L. Rudel. 1985. Alteration of high density lipoprotein subtraction distribution with induction of serum amyloid A protein (SAA) in the nonhuman primate. J. Lipid Res. 26: 82-91.
14. Ly, H., O. L. Francone, C. J. Fielding, J. K. Shigenaga, A. H. Moser, O. Grunfeld, and K. R. Feingold. 1995. Endotoxin and TNF lead to reduced plasma LCAT activity and decreased hepatic LCAT mRNA levels in Syrian hamsters. J. Lipid Res. 36: 1254-1263.
15. Hardardottir, I., S. T. Kunitake, A. H. Moser, W. T. Doerrler, J. H. Rapp, C. Grunfeld, and K. R. Feingold. 1994. Endotoxin and cytokines increase hepatic messenger RNA levels and serum concentrations of apolipoprotein J (clusterin) in syrian hamsters. J. Clin. Invest. 94: 1304-1309.
16. Walsh, A., Y. Ito, and J. L. Breslow. 1989. High levels of human apolipoprotein A-I in transgcnic mice result in increased plasma levels of small high density lipoprotein (HDL) particles comparable to human HDL3. J. Biol. Chem. 264: 6488-6494.
17. Rubin, E., R. Krauss, E. Spangler, J. Verstuyft, and S. Clift. 1991. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 353: 265-267.
18. Chajek-Shaul, T., T. Hayek, A. Walsh, and J. L. Breslow. 1991. Expression of the human apolipoprotein A-I gene in transgenic mice alters high density lipoprotein (HDL) particle size distribution and diminishes selective uptake of HDL cholesteryl esters. Proc. Natl. Acad. Sci. USA. 88: 6731-6735.
19. Kozarsky, K. F., and J. M. Wilson. 1993. One therapy: adenovirus vectors. Curr. Opin. Genet. Dev. 3: 499-503.
20. Webb, N. R., M. C. de Beer, D. R. van der Wethuyzen, M. S. Kindy, C. L. Banka, K. Tsukamoto, D. L. Rader, and F. C. de Beer. 1997. Adenoviral vector-mediated overexpression of serum amyloid A in apoA-I-deficient mice. J. Lipid Res. 38: 1583-1590.
21. Ye, X., M. Robinson, M. Batshaw, E. Furth, I. Smith, and J. M. Wilson. 1996. Prolonged metabolic correction in adult ornithine transcarbamylase-deficient mice with adenoviral vectors. J. Biol. Chem. 271: 3639-3646.
22. Tsukamoto, K., P. Smith, J. M. Glick, and D. J. Rader. 1997. Liver-directed gene transfer and prolonged expression of three major human apoE isoforms in apoE deficient mice. J. Clin. Invest. 100: 107-114.
23. Tsukamoto, K., K. G. Jiester, P. Smith, D. C. Usher, J. M. Glick, and D. J. Rader. 1997. Comparison of human apoA-I expression in mouse models of atherosclerosis after gene transfer using a second generation adenovirus. J. Lipid Res. 38: 1869-1876.
24. Masucci-Magoulas, L., P. Moulin, X. C. Jiang, H. Richardson, A. Walsh, J. L. Breslow, and A. Tall. 1995. Decreased cholesteryl ester transfer protein (CETP) mRNA and protein and increased high density lipoprotein following lipopolysaccharide administration in human CETP transgenic mice. J. Clin. Invest. 95: 1587-1594.
25. Hoffman, J., and E. Benditt. 1982. Changes in high density lipoprotein content following endotoxin administration in the mouse: formation of serum amyloid protein-rich subfractions. J. Biol. Chem. 257: 10510-10517.
26. Nevalainen, T. 1993. Serum phospholipases A2 in inflammatory diseases. Clin. Chem. 39: 228-238.
27. 2: influence on lipoprotein metabolism. J. Lipid Res. 38: 2232-2239.